Sareum Holdings (SAR) Short Positions
Add to Alert list

Active Short Positions

Holder Position Change Date
No active short positions

Historical Short Positions

Holder Position Change (%) Date
No historical short positions

Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.

The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.

It listed on AIM in 2004 under the ticker SAR.

Note: This description is in part generated by AI and not an endorsement by or the opinion of Investegate
UK 100

Latest directors dealings